Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918211 · ClinicalTrials.gov registry record · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
A Phase 3 study of Single Ventricle Heart Disease, sponsored by Mezzion Pharma Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 436
- Enrollment target
- 20
- Study locations
NCT05918211 is a Phase 3 study of Single Ventricle Heart Disease that is actively recruiting participants, run by Mezzion Pharma Co.. The registered enrollment target is 436 participants, above the 116-participant average among 4 other Single Ventricle Heart Disease trials with a reported enrollment target (276% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05918211, a Phase 3 study of Single Ventricle Heart Disease, is actively recruiting participants, sponsored by Mezzion Pharma Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 436 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Udenafil
Study Locations (20)
California
- Children's Hospital of Los Angeles - Los Angeles
- Rady Children's Hospital - San Diego
- UCSF Benioff Children's Hospital - San Francisco
Florida
- UF Health Shands Hospital - Gainesville
- Joe DiMaggio Children's Hospital - Hollywood
- Johns Hopkins All Children's Hospital - St. Petersburg
Georgia
- Children's Healthcare of Atlanta - Atlanta
- Children's Hospital of Georgia - Augusta
Illinois
- Lurie Children's Hospital - Chicago
- University of Chicago - Chicago
Missouri
- Children's Mercy Hospital Kansas City - Kansas City
- Washington University - St Louis
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's - Little Rock
Colorado
- Children's Hospital of Colorado - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 436 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2025-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05918211
The ClinicalTrials.gov registry entry for NCT05918211 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 436 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 116-participant average among 4 other Single Ventricle Heart Disease trials with a reported enrollment target (276% higher). The listed sponsor is Mezzion Pharma Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Single Ventricle Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05918211 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05918211 about?
NCT05918211 is a clinical study titled "Fontan Udenafil Exercise Longitudinal Assessment Trial - 2". This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
What is the current status of trial NCT05918211?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 436 participants. The study started on 2023-10-30. Estimated completion is 2025-10-28.
What conditions does trial NCT05918211 study?
This clinical trial studies the following conditions: Single Ventricle Heart Disease.
What interventions are being tested in trial NCT05918211?
The interventions under investigation include: Placebo (DRUG), Udenafil (DRUG).
Who is sponsoring clinical trial NCT05918211?
This trial is sponsored by Mezzion Pharma Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918211 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Single Ventricle Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fontan Udenafil Exercise Longitudinal Assessment Trial
COMPLETED · Phase 3
-
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
RECRUITING · Phase 2
-
WE BEAT - HEART Club Fontan Wellness Project: A Virtual Resilience Promotion and Frailty Prevention Program
ACTIVE NOT RECRUITING · NA
-
Cognitive Intervention to Improve Working Memory
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.